Treatment of unresectable recurrent head and neck carcinoma with 13-cis-retinoic acid and interferon-α. A phase II study

Journal of Laryngology and Otology

Volumn 110, Issue 9, 1996, Pages 857-861

  Nikolaou, Angelos C ^a   Fountzilas, George ^a   Daniilidis, Ioannis ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Carcinoma; Head and neck neoplasms; Interferon alpha; Retinoids

Indexed keywords

ALPHA INTERFERON; ISOTRETINOIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOXICITY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; INOPERABLE CANCER; MALE; NECK; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; TUMOR REGRESSION;

EID: 0029823128     PISSN: 00222151     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0022215100135169     Document Type: Article

References (18)

1. Clark, J. R., Frei, E. III. (1989) Chemotherapy for head and neck cancer: Progress and controversy in the management of patients with Mo disease. Seminars of Oncology 16: 44-57.
2. Clayman, G. L., Liu, F. J., Savage, H. E., Taylor, D. L., Lavedan, P., Buchsbaum, R. M., Pellegrino, C., Trujillo, J. M., Young, G., Schantz, S. P. (1992a) Acute-phase proteins in patients with head and neck cancer treated with interleukin 2/interferon alfa. Archives of Otolaryngology, Head and Neck Surgery 118: 41-47.
3. Clayman, G. L., Young, G., Taylor, D. L., Savage, H. E., Lavedan, P., Schantz, S. P. (1992b) Detection of regulatory factors of lymphokine-activated killer cell activity in head and neck cancer patients treated with interleukin-2 and interferon-α. Annals of Otology, Rhinology and Laryngology 101: 909-915.
4. Crispino, S. (1993) The use of interferon in head and neck cancer: A clinical review. Forum 34: 384-392.
5. Dmitrovsky, E., Bosl, G. J. (1992) Active cancer therapy combining 13-cis-retinoic acid with interferon-α. Journal of National Cancer Institute 84: 218-219.
6. Fierro, R., Johnson, J., Myers, E., Colao, D., Pelch, K., Rust, D., Wagner, R., Whiteside, T., Vlock, D. (1988) Phase-II trial of non-recombinant interferon-α (IFN) in recurrent squamous cell carcinoma of the head and neck (Abstract). Proceedings of the American Society of Clinical Oncology 7: 156.
7. Fountzilas, G. (1994) Retinoids in the management of head and neck cancer. An update. Journal of Chemotherapy 6(2): 127-138.
8. Knobler, R. M., Trautinger, F., Radaszkiewicz, T. (1991). Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. Journal of the American Academy of Dermatology 24: 247-252.
9. Lippman, S. M., Kavanagh, J. J., Paredes-Espinoza, M., Delgadillo-Madrueno, F., Paredes-Casillas, P., Hong, W. K., Holdener, E., Krakoff, I. H., (1992a) 13-cis-Retinoic acid and interferon-alfa 2a: High activity systemic therapy for squamous cell carcinoma of the cervix. Journal of National Cancer Institute 84: 241-245.
10. Lippman, S. M., Parkinson, D. R., Itri, L. M., Weber, R. S., Schantz, S. P., Ota, D. M., Schusterman, M. A., Krakoff, I. H., Gutterman, J. U., Hong, W. K. (1992b). 13-cis-Retinoic acid and interferon-α 2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. Journal of National Cancer Institute 84: 235-241.
11. Nikolaou, A., Fountzilas, G., Themelis, C., Daniilidis, J. (1993). Treatment of unresectable recurrences of the head and neck carcinomas with interferon-α and retinoids (Abstract). Proceedings of the 15th World Congress of Otorhinolaryngology - Head and Neck Surgery, Istanbul, pp. 360.
12. Richtsmeier, W. J., Koch, W. M., McGuire, W. P., Poole, M. E., Chang, E. H. (1990) Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Archives of Otolaryngology, Head and Neck Surgery 116: 1271-1277.
13. Rosenberg, S. A., Schwartz, S., Speiss, P. J. (1988) Combination immunotherapy for cancer: synergistic antitumour interactions of interleukin-2 alpha-interferon, and tumour infiltrating lymphocytes. Journal of National Cancer Institute 80: 1393-1397.
14. Schantz, S. P., Clayman, G. L., Racz, T., Grimm, E. A., Liu, F. J., Lavedan, P., Taylor, D., Pellegrino, C., Savage, H. (1990) The in vivo biologic effect on interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer. Archives of Otolaryngology, Head and Neck Surgery 116: 1302-1308.
15. Smith, M. A., Parkinson, D. R., Cheson, B. D., Friedman, M. A. (1992) Retinoids in cancer therapy. Journal of Clinical Oncology 10: 839-864.
16. Tannock, I. F., Browman, G. (1986) Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer? Journal of Clinical Oncology 4(7): 1121-1126.
17. Taylor, S. G. (1987) Why has so much chemotherapy done so little in head and neck cancer? Journal of Clinical Oncology 5(1): 1-3.
18. Voravud, N., Lippman, S. M., Weber, R. S., Rodriquez, G. I., Yee, D., Dimery, I. W., Earley, C. L., Von Hoff, D. D., Ki Hong, W. (1993) Phase II trial of 13-cis-retinoic acid plus interferon-α in recurrent head and neck cancer. Investigational New Drugs 11: 57-60.